Form 4: Akebia Therapeutics Officer Sells Shares for Tax Obligations
Insider Transaction Report
Akebia Therapeutics' SVP and Chief Accounting Officer, Richard C. Malabre, sold shares to cover tax withholding obligations related to RSU vesting.
Summary
- Richard C. Malabre, SVP, Chief Accounting Officer of Akebia Therapeutics, Inc. (AKBA), sold a total of 49,524 shares of common stock.
- The sales occurred on February 2, 2026, at a price of $1.39 per share.
- These transactions were executed automatically by the Issuer to cover tax withholding obligations.
- Specifically, 36,142 shares were sold due to the vesting of restricted stock units granted on January 31, 2024.
- An additional 13,382 shares were sold due to the vesting of restricted stock units granted on January 31, 2025.
- The sales were conducted under a Rule 10b5-1 trading plan adopted on September 8, 2025.
- Following these transactions, Mr. Malabre beneficially owns 299,390 shares of Akebia Therapeutics common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event. The sale is administrative, pre-planned, and solely for tax purposes, not indicative of a change in sentiment regarding the company's future.
Future Outlook
No forward-looking statements or guidance are provided in this filing.
Industry Context
StockSavvy.ai notes that routine insider sales for tax withholding purposes, especially when executed under a pre-arranged 10b5-1 plan, are common and typically do not signal a change in management's outlook on the company's prospects.
Comparison to Industry Standards
- This type of transaction is standard practice across publicly traded companies when restricted stock units vest, as it allows executives to cover tax liabilities without needing to use personal funds or make discretionary sales. No specific comparable companies or projects are relevant for this routine administrative filing.
Stakeholder Impact
- Minimal impact on shareholders, employees, customers, suppliers, or creditors, as this is a routine administrative transaction related to executive compensation.
Key Dates
| Date | Description |
|---|---|
| 2024-01-31 | Grant date of restricted stock units, one-third of which vested and led to a tax withholding sale. |
| 2025-01-31 | Grant date of restricted stock units, one-third of which vested and led to a tax withholding sale. |
| 2025-09-08 | Date Rule 10b5-1 trading plan was adopted by Richard C. Malabre. |
| 2026-02-02 | Transaction date for the sale of common stock to cover tax withholding obligations. |
| 2026-02-04 | Signature date of the reporting person's attorney-in-fact. |
Recommendation
holdThis Form 4 reports a routine, pre-planned sale of shares by an officer to cover tax obligations associated with RSU vesting. Such transactions are administrative in nature and do not typically reflect a change in the officer's or company's outlook, thus warranting no change in investment recommendation based solely on this filing.
Keywords
Akebia Therapeutics, AKBA, Form 4, Insider Trading, Richard C. Malabre, Restricted Stock Units, RSU, Tax Withholding, Rule 10b5-1, Officer Stock Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.